# Business Plan



**A globally leading biotech company specializing in innovative drugs,**
**powered by a intergrated platform combining DEL (DNA-encoded Libraries) and AI technologies.**

# Project Background

Global Trend | Small-Molecule

# Opportunities and Challenges




Source: https://www.precedenceresearch.com/small-molecule-drug-discovery-market





AstraZeneca Inks Licensing Deal With China's CSPC for Early Stage Lipid-Lowering Therapy

TANG SHIHUA X
DATE: OCT 08 2024 / SOURCE: YICAI

0:00 / 2:37



*AstraZeneca Inks Licensing Deal With China's CSPC for Early Stage Lipid-Lowering Therapy*

- The global small molecule drug discovery market is estimated to reach $88.57 billion in 2024 and is projected to grow to approximately $190.68 billion by 2034, with a compound annual growth rate (CAGR) of 7.97% during the period from 2024 to 2034.
- In recent years, the license-out of Chinas innovative drug pipelines has become the mainstream approach for overseas expansion, with small-molecule chemical drugs still accounting for the largest share (20–25%).

# Opportunities and Challenges

| Field | Limitations | Solutions |
|---|---|---|
| **New Drug Development (Small Molecule)** | • Long duration, high risk, high capital invest<br>• Me too — Fast follow — FIC?<br>• Lack of effective high-throughput screening tools for challenging targets (PPI, membrane proteins) and novel modalities (molecular glues, radiopharmaceuticals). | Compared to other screening methods, DEL achieves higher success rates in identifying active compounds, particularly advantageous for drug discovery targeting FIC sites, challenging targets, and novel therapeutic modalities, while significantly reducing both costs and time requirements. |
| **AIDD** | • Lack of high-quality real-world experimental training data | The DEL selection generates a large volume of high-quality real-world experimental datasets for model training, particularly those containing a substantial number of negative samples. |
| **DEL** | • The filtered data exhibits high noise levels (particularly in cell screening), and data analysis is time-consuming.<br>• Capable of rapidly and efficiently obtaining lead compounds, but lacks sufficient structural optimization capabilities. | AI-assisted data analysis significantly enhances efficiency in the DEL screening process by employing noise reduction algorithms to extract valid data and leveraging conventional AIDD techniques to accelerate continuous optimization from hits to leads. |

**The NewDEL platform employs integrated technologies centered on DEL+AI to address key challenges in new drug discovery.**

# The Development History

**Jul, 2021**

Angel financing led by Cowin Capital

**Jun 2022**

Pre-A round financing led by Bioching Capital and followed by Cowin Capital

**Jul, 2023**

Pre A+ round financing completed

**Mar, 2024**

Series A financing completed.

**March, 2025**

Series A+ financing: Xtalpi led the investment

**Jan, 2026**

Series A+ financing: Xtalpi continued the investment

**2021** | **2022** | **2023** | **2024** | **2025** | **2026**

**Apr, 2021**

founded as the first biotech company incubated by SMD.

**Oct, 2022**

DEL+AI platform established

**May - Dec, 2023**

Formed new drug development technical service cooperations with two large domestic listed pharma companies

**Nov, 2024**

Breakthrough in functional DEL screening in live cells

**Apr-Oct, 2025**

The overseas expansion of technical services with 2 European MNCs.

**May, 2026**

MNC Company will continue with the next stage of cooperation

# Platform Overview

DELCELLIX | DELNEXUS

# Drug Discovery Technology Platform

## Artificial Intelligence in Drug Development and Design (AIDD)




- Speed: Screen billions of compounds in a matter of hours, accelerating drug discovery;
- Chemical Space: The generative model transcends known compound libraries to explore a more diverse chemical space.
- Accuracy: Data-driven approaches overcome computational bottlenecks and enhance prediction accuracy.

XtalPi Atomwise Insilico Medicine RELAY THERAPEUTICS

Schrödinger Exscientia AbCellera RECURSION

## DNA-encoded Library Technology (DEL)



- **10 ~ 200 μL**
- **fmol compound**

- Large molecular library scale:> 1 trillion compound libraries;
- Short screening period: 4–8 weeks;
- Comprehensive information: Preliminary SAR results can be obtained through filtered data analysis.


*Nat. Chem. Biol*. **2009**, *5*, 647.
*Nat. Rev. Drug Discov*. **2017**, 16, 131.
*Nat. Rev. Methods Primers*. **2022**, *2*(1), 3.
*Nat. Rev. Drug. Discov*. **2023**, 22, 699.


GSK X-CHEM

AstraZeneca janssen Pfizer MERCK

HITGEN abbvie NOVARTIS WuXi AppTec

**high efficiency**
**low cost**
**High compatibility**

# DEL as a Key Platform for Difficult Target Hit Discovery

**Roche: Only DEL is used in 100% of projects and shows the highest lead conversion (~38%)**




DEL is Universally Applied




DEL Shows Highest Conversion

- **Platform Dominance:** DEL is the only method applied across all projects (100% usage)
- **Superior Efficiency:** DEL delivers the highest hit-to-lead conversion (~38%)
- **Strategic Role:** DEL enables early ligandability assessment and guides downstream screening

ACS Med. Chem. Lett. 2026. https://doi.org/10.1021/acsmedchemlett.5c00676

# DEL+AI Integration: A Next-Generation Engine for New Drug Discovery

## Application




novel small-molecule drugs
DEL@SMD




New Radiopharmaceuticals
DEL@RDC



New Cyclopeptide Drugs
DEL@MCP



Novel Protein Degraders
DEL@TPD

New Agrochemicals
DEL@ACD

o o o

## Technology




Single-stranded DNA labeling



Live Cell Screening
DELCELLIX®-V1




Functional Screening of Live Cells
DELCELLIX®-V2

Organoid Screening

o o o

## Foundation

**100Bn+ DNA-encoded compound library (physical library)**

Partners

XtalPi

DEL Data

High Performance Computing

# NewDEL Technology: ssDEL + live-cell screening

| Field | Technology | HitGen | Wuxi | X-chem | Vipergen | We |
|---|---|---|---|---|---|---|
| **Library Generation** | DNA Tag | Double stranded | Double stranded | Double stranded | Double stranded | Single Stranded |
| **Screening** | Target Protein | √ | √ | √ | √ | √ |
| | Cell-line | × | × | × | √ (in cell) | √ (on cell) |
| | Functional | × | × | × | × | √ (on cell/PROTAC) |
| **Combo Tech** | AI+ | √ (w/ partner) | √ (in-house) | √ (in-house) | × | √ (in-house) |

| Property | Single-stranded (ss) DEL | Double-stranded (ds) DEL |
|---|---|---|
| **Physical size** | Smaller hydrodynamic radius (~2 nm); more flexible | Larger (~4 nm); stiffer double helix |
| **DNA lengths** | ~50-80bp for 2-3 cycles | ~80-90bp for 2-3 cycles |
| **Steric hindrance to target** | Minimal; ligand often behaves like a free small molecule | Greater; dsDNA rod can clash with binding pockets |
| **Hybridization handles** | Free bases allow hybridization | Limited accessibility |
| **Encoding methods for DEL constructions** | OBOC, DTS, YactorReactor, DNA routing, ESAC, PNA encode library, DEDL | Headpiece, DNA polymerization |
| **Targets** | Purified targets, cell lysate, live cell | Purified targets, live cell with protein overexpression |
| **Application** | hit discovery, lead extension of hit compounds | hit discovery |

**DEL libraries can be screened in both single- and double-stranded DNA formats, while single-stranded DEL could give better enrichment performance and enable versatile applications.**

Angew. Chem. Int. Ed. 2025, 64, e202511839.
Nat Rev Drug Discov. 2023, 22, 699-722.
Angew. Chem. Int. Ed. 2023, 62,e202215542.
ChemBioChem. 2022, 23, e202200025.

# Global leader – DEL Live Cell Screening Technology




POI labeled with a DNA tag

ligand guided selection



site specific selection






photoaffinity labeling selection




cell-based agonist selection




**The right figure proposed a representative cell-based selection method. With a guiding DNA bearing a known ligand, single-stranded DELs are guided to selectively interrogate POI with an elevated local concentration, after which the ligand is cleaved to facilitate removal of non-binders from the cell surface. After washing steps, the hit compounds were eluted, decoded with PCR amplification and DNA sequencing.**

- Paper on Live-Cell Screening with DEL Technology: *Nat. Chem.*, **2021**, 13(1):77;
- Patent on Live-Cell Screening with DEL Technology: CN202010213128;
- Additional patents are publicly available (CN202410693265.8, CN202410848793.6).

- Representative projects for DEL live cell screening: ND-002, ND-013

# Global leader – DEL Live Cell Screening Technology - V2.0

## V2.0 Evolution: From affinity to functionality

- Currently most DEL selections only guarantee binding affinities, while drug development requires biological activities.
- Low molecular concentration in DEL selections limit activating/inhibitory performance of potential bioactive molecules.
- Functional DEL selections requires special methodology design.




In collaboration with Prof. Xiaoyu Li, the University of Hong Kong

- Representative case of functional screening of DEL live cells: insulin receptor allosteric agonist

# DEL Live Cell Screening Case: ND-002




- A DEL library with a scale of 1 billion entries for live-cell screening targeting CD73 was employed.
- After screening, 20 compounds were selected for off-DNA synthesis.
- The lead compound was identified through biological evaluation, with an $IC_{50}$ value of 1.7 μM.




**Target：CD73**

CD73 plays an pivotal role in adenosine accumulation that contributes to cancer immune evasion and is overexpressed on various cell types within an immunosuppressive tumor microenvironment (TME). Thus, Small-molecular inhibitors targeting CD73 is promising in clinical trials as a single agent or in combination with other immunotherapies.

**Type:** In-house

**Competition:** The CD73 race is a high-stakes pivot toward Phase III validation (led by Quemliclustat in pancreatic cancer and Oleclumab in NSCLC).

*Chem. Biol.*, **2011**, 18, 1284; *Angew. Chem.* **2013**, 52, 9544;
*ACS Comb. Sci.*, **2015**,17, 722; *J. Am. Soc. Chem.*, **2019**, 141, 17057.

# DEL Live Cell Screening Case: ND-013

Article

## Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion

https://doi.org/10.1038/s41586-021-04057-2
Received: 18 October 2019
Accepted: 22 September 2021
Published online: 3 November 2021
Check for updates

Xiujie Sun[1,11], Bogang Wu[1,11], Huai-Chin Chiang[1,11], Hui Deng[2], Xiaowen Zhang[1], Wei Xiong[2], Junquan Liu[2], Aaron M. Rozeboom[3], Brent T. Harris[3], Eline Blommaert[4], Antonio Gomez[5], Roderic Espin Garcia[4], Yufan Zhou[6], Payal Mitra[7], Madeleine Prevost[1], Deyi Zhang[8], Debarati Banik[1], Claudine Isaacs[3], Deborah Berry[3], Catherine Lai[3], Krysta Chaldekas[3], Patricia S. Latham[9], Christine A. Brantner[10], Anastas Popratiloff[10], Victor X. Jin[6], Ningyan Zhang[2], Yanfen Hu[7], Miguel Angel Pujana[4]✉, Tyler J. Curiel[8]✉, Zhiqiang An[2]✉ & Rong Li[1]✉




**The DDR1 extracellular domain (DDR1-ECD), but not its intracellular kinase domain, is responsive for immune exclusion.**

**Target：DDR1 - ECD**

**Type：In house**

**Competition:** No current approved drugs on the market.

| Entry | Inhibitor | Collagen Binding $IC_{50}$/uM | DDR1-ECD (Kd) |
|---|---|---|---|
| 1 | NDDP-D4 | 2.25 | **4.15 uM** |
| 2 | NDDP-D5 | 51.07 | |
| 3 | NDDP-D6 | 53.87 | |
| 4 | **NDDP-D7** | **2.064** | **21.3 uM** |
| 5 | NDDP-D8 | 122.6 | |
| 6 | NDDP-D9 | 26.77 | |
| 7 | NDDP-D10 | 174.8 | |
| 8 | NDDP-D11 | 6.648 | **21.4 uM** |
| 9 | NDDP-D12 | 5.105 | **8.35 uM** |

# DEL+AI Integration: A Drug Evolution Engine Based on DEL Data

**DELNEXUS® Technology Platform**




**Bring evolution mindset into Drug Discovery**

## Building the data foundation for the large-scale DL model



- Precise Noise Reduction
- Customized Processing Workflow

## Virtual Screening and Quantification of Uncertainty




- Precise Prediction
- Feature Generalization
- Quantification of Uncertainty and Applicable Domains

## Molecular generation driven by large-scale chemical language models




- Wide chemical spatial coverage
- Easy to synthesize

## "Pre-training + Fine-tuning" ADMET prediction




- Multi-source data integration
- Comprehensive analysis of atomic and chemical bond topological information

# DEL+AI Integration: Combining Dry and Wet Experiments in Drug Discovery


DELNEXUS® Technology Homepage




AI assisted DEL Data Analysis




AI assisted Molecule Search




AI empowered virtual screening




AI assisted Molecular Generation




AI based ADMET Prediction

**Target Compounds**

- Advanced data processing and generation as well as model training and prediction.
- Comprehensive structural optimization procedure.
- Detailed ADMET prediction capabilities.

**Publications integrating AI and DEL screening：**

- Active Discovery Model：Front. Chem., **2022**, *26*: 982539
- Molecular Generation：Front. Pharma., **2022**, *13*:1085665

# DEL+AI Technology Case Study: ND-C02




**Target:** Not disclosed; FIC-class target

**Type:** Technical Service

**Results:** The DEL screening identified a series of active compounds with significant inhibitory effects, among which the most potent compound exhibited an IC50 of approximately 13 nM, along with low CYP inhibition risk and minimal hERG toxicity. By integrating AI-driven molecular design with medicinal chemistry approaches to optimize molecules across multiple core architectures, and through ADMET predictions coupled with wet-lab validation, several lead compounds with IC50 around 2 nM were developed, with demonstrated favorable pharmacokinetic (PK) profiles.

# DEL+AI Technology Case Study: ND-018




DEL screening & Hit Analysis




Core Determination



Similarity Exploration in Commercial Libraries



CADD Simulation & Validation




Enzymatic Assay

Hit Compound
NDDP-1198
IC50: 260 nM

6
AI/CADD




Enzymatic Assay

Warhead pre-Lead
NDDP-1230
IC50: 10 nM

6
AI/CADD




Degradation Assay

Protac
NDDP-1254
DC50: 202 nM

**Type:** In-house

**Results:** The DEL screening yielded a series of promising lead compounds with strong inhibitory effects. Through the DELNEXUS platform optimization, multiple 10 nM Warhead molecules were obtained. Finally, the PROTAC molecule DC50 was constructed with a potency of 202 nM.

# DEL@RDC: Overcoming Core Bottlenecks in RDC Drugs







## Bottlenecks in RDC Development




- **01** Limited Access to Ultra-High-Affinity Ligands
- **02** Insufficient Tumor Selectivity
- **03** Poor Translation to In Vivo Performance

## DEL-Enabled Advantages

- Discovery of Ultra-High-Affinity Binders
- Early Selectivity Profiling
- Optimization of Binding Kinetics
- Enabling Effective Radioligand Performance
- Modular Transition to Radioligands


Eur J Nucl Med Mol Imaging. 2025 Jun;doi: 10.1007/s00259-025-07103-7
Georgiev et al., Nat. Biomed. Eng. 2025: DOI: 10.1038/s41551-025-01432-6
Poupart et al., Bioconjugate Chem., 2026.37(3), 511–525.

# DEL@MCP Peptide Drug Discovery




**Small macrocycles**
3-7 natural/unnatural amino acids
Library size > 3 billion

## Characteristics of one typical MCP DEL library




**Advantages and characteristics in constructing a DNA-encoded cyclic peptide compound library:**

1.The library contains a wide variety of molecular building blocks: Fmoc-protected amino acids and their derivatives, totaling over 800 types.

2. High-quality sample preparation: Strict quality control (QC): HPLC purification + MS analysis; 100% comprehensive detection via enzyme-linked reactions.

3. The peptide library exhibits excellent physicochemical properties.

# DEL@MCP Case: ND-017

**Target：IL-23R**

IL-23R binds to IL-23 to activate JAK and STAT signaling molecules, mainly activates STAT3, thereby regulating the release of pro-inflammatory cytokines by IL-23/IL-17 signaling pathway.

**Type：** In house

**Competition:** Currently, there are four approved antibody drugs targeting IL-23 on the market, with only one peptide drug just approved.



DEL hit: **I-1**




DEL hit: **I-2**









# Team introduction

Core Team | Chief Scientist | Technical Team

# The company core team

## Chairman: He Xun



- Master Degree in Biochemical Engineering from Tsinghua University, EMBA from the National University of Singapore, Certificated Professor Level Senior Engineer.
- Member of the 8th National Pharmacopoeia Commission; Member of the 3rd Shenzhen Science and Technology Expert Committee; Expert for Drug Production Quality Risk Assessment at the 4th Shenzhen Municipal Level; Founder of the Shenzhen Life Sciences and Biotechnology Association.
- Currently serves as Chairman of the Guangdong Small Molecule New Drug Innovation Center, Chairman of Shenzhen We Biotechnology Co., Ltd., and General Manager of Shenzhen Weiming Xinpeng Biopharmaceutical Co., Ltd.
- Ever served as General Manager at Shenzhen Kexing Biological Products Co., Ltd., Shandong Kexing Biological Products Co., Ltd., Tianjin Weiming Biopharmaceutical Co., Ltd., Shenzhen Resproly Biopharmaceutical Co., Ltd., and Shanghai Longyao Biotechnology Co., Ltd.
- Professional capabilities in fundraising, investment management, and exit strategies, achieving returns exceeding 10-fold for multiple innovative pharmaceutical enterprises;
- Reviewed 10,000+ biopharmaceutical projects spanning areas including biological products, chemical drugs, traditional Chinese medicine, diagnostic reagents, medical devices, and medical technologies
- 30+ years of expertise in the comprehensive healthcare sectors

# The company core team

## CEO: Dr. Xiong Feng

Ph.D. graduate from Nanjing University and postdoctoral fellow at the UKU; C high-level overseas talent in Shenzhen. Under the supervision of Professor Xiaoyu Li , a world famous expert in DNA-encoded library technology. Proficient in the design, synthesis, and application of DNA-encoded compound libraries in drug screening, with extensive research experience in medicinal chemistry and the field of DNA-encoded libraries.

## CMO: Shang Beicheng

Graduated from the Second Military Medical University in 1991, masters degree from Kunming Medical University. Currently serves as Associate Chief Pharmacist and Licensed Pharmacist, with 25+ years of experience in clinical research on new drugs; worked at Kunming General Hospital of Chengdu Military Region on formulation optimization and clinical trials. Since 2010, he has held positions including Clinical Director and Senior Clinical Director at pharmaceutical companies.

## VP: Zhang Shuihua

Master of Biotechnology from Shanghai JiaoTong University; participated in projects that secured 1 biologics production approval and 9 clinical trial approvals; successfully acquired multiple pharmaceutical companies and invested in several biopharmaceutical and chemical drug development projects.

# Expert Advisory Team

## Advisor on DEL: Prof. Dr. Xiaoyu Li

Professor at HKU, PhD at U Chicago , Postdoc at Harvard, 20+ years in DNA-encoded libraries research.

## Advisor on CADD/AIDD: Prof. Dr. Jun Xu

Professor and director at Sun Yat-sen University, expert in drug molecular design, former lead drug design scientist at a Top10 pharma company.

## Advisor on ND-003: Prof. Dr. Ke Ding

Professor at SIOC and School of Pharmacy at JNU. 70+ patents granted, multiple new drug pipelines commercialized.

## Advisor on CADD/AIDD：Prof. Dr. Jianping Lin

Professor at Nankai University, specialized in AIDD/CADD, incl. molecular simulation, drug design, and biological databases and mining.

## Advisor on Metabolism: Prof. Dr. Shangyu Hong

Professor at Fudan University, genetic engineering lab PI, focusing on diet, nutrition, and metabolism.

# Business Model

Technology Platform | In-house Pipeline | Collaboration

# Business Model: Two Pillars – Technical Service and in-house R&D

## Technical Service

DEL Screening and New Drug Development Services

DEL Custom Library Screening and Optimization Service

AI Virtual Screening Service

## Target Customer

MNC, Biotech

## Profit Model

FFS, EFS

## In-house R&D

0–1: Rapid and low-cost project accumulation

Radiopharmaceutical Pipeline Development

Peptide Drug Pipeline Development

## Target Customer

MNC, Pharma & Hospitals

## Profit Model

Out-licensing, JV, NewCo

# DEL+AI Platform well recognized and validated within the industry

| | Project | Area | Hit | Lead | PCC | IND-enabling | Client type | Progress |
|---|---|---|---|---|---|---|---|---|
| FFS | ND-C01 | FIC, Hit Delivery | | | | | Domestic public BigPharm | Completed |
| | ND-C02 | FIC, PCC Delivery | | | | | Domestic public BigPharm | Lead to PCC |
| | ND-C03/05/06 | Epigenetic, Overseas→CN | | | | | Domestic Biotech | Completed |
| | ND-C04 | Agrochemical, Cell Screen | | | | | European MNC | Completed |
| | ND-C07 | PPI, Cell Screen | | | | | TOP10 MNC | Completed |

- The cumulative amount of technical service contracts has exceeded 5 million USD.
- Multiple projects have achieved milestone deliveries ahead of contract schedule.

# In-house product portfolio: Multiple high-value preclinical projects

| ID | Target/MoA | Indications | Type | Hit-to-Lead | Lead-to-PCC | PCC-to-IND | Phase1 | Phase2 |
|---|---|---|---|---|---|---|---|---|
| ND-005 | ADAR1 | Solid tumor（PROTAC） | In-house | | | | | |
| ND-018 | IRAK4 | Autoimmune（PROTAC） | In-house | | | | | |
| ND-021 | \ | \ | In-house | | | | | |
| ND-014 | New E3 ligase | \ | In-house | | | | | |
| ND-017 | IL23R | Autoimmune | In-house | | | | | |
| ND-023 | \ | Solid tumor (RDC) | In-house | | | | | |
| ND-024 | \ | \ (RDC) | In-house | | | | | |

- The revenue generated from the licensing transfer of preclinical pipelines will support the expansion of the DEL+AI engine and platform, further driving subsequent pipelines into a new phase of value growth.
- By combining "rapid commercialization with technological accumulation," a dual closed-loop system for cash flow and valuation is established.

# Strategic Planning

Technology Platform Development | Pipeline Construction | Capitalization Path

# Development Plan and Financing




The proposed funding amount for this round ranges from RMB 30 million to RMB 50 million, primarily intended for the following purposes:

1.Construct the next geneartion of DEL technology platform

2. Upgrade and integrate the AI technology platform

3. Bring the in-house pipeline to the IND stage4.

Expand into more international markets



We look forward to working with you hand in hand to create new value together

Thank you for your interests